ERCP in Idiopathic Recurrent Acute Pancreatitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01583517 |
Recruitment Status :
Completed
First Posted : April 24, 2012
Last Update Posted : October 10, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Recurrent Acute Pancreatitis | Procedure: Biliary sphincterotomy Procedure: Pancreatobiliary sphincterotomy Procedure: Sham | Not Applicable |
Patients with idiopathic RAP, defined as ≥2 unexplained (per the treating physician) episodes of acute pancreatitis (based on standard criteria) requiring hospitalization, will be prospectively enrolled. All patients will undergo ERCP with manometry, with stratified randomization based on the assessment of pancreatic basal sphincter pressure. If <40mmHg, the patient will be randomized to sham or biliary sphincterotomy (BES). If ≥40mmHg, the patient will be randomized to BES or pancreatobiliary ("dual") sphincterotomy (DES).
Patients and physicians will not be blinded to the assignment group. Patients will be followed for up to 10 years to determine 1) incidence of RAP requiring hospitalization (using standard definitions) or 2) interval development of chronic pancreatitis (CP).
Differences between patients who did and did not develop RAP during follow-up will be compared to evaluate for factors associated with AP during follow-up.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 89 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Defining the Role of ERCP in the Evaluation and Treatment of Idiopathic Recurrent Acute Pancreatitis |
Study Start Date : | September 1997 |
Actual Primary Completion Date : | April 2012 |
Actual Study Completion Date : | October 2014 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Biliary sphincterotomy
Cutting of the biliary sphincter muscle alone
|
Procedure: Biliary sphincterotomy
Cutting of the biliary sphincter muscle. |
Active Comparator: Dual sphincterotomy
Cutting of both the biliary and pancreatic sphincter muscles.
|
Procedure: Pancreatobiliary sphincterotomy
Cutting of both the biliary and pancreatic sphincter muscles. |
Sham Comparator: Sham
Among patients with normal sphincter of Oddi manometry, patients will undergo no sphincterotomy (sham therapy).
|
Procedure: Sham
No sphincterotomy is performed in patients randomized to sham with normal SOM. |
Active Comparator: Biliary sphincterotomy - Normal SOM
Among patients with normal SOM, patients may be randomized to empiric biliary sphincterotomy alone.
|
Procedure: Biliary sphincterotomy
Cutting of the biliary sphincter muscle. |
- Recurrent acute pancreatitis [ Time Frame: 120 months ]
Patients will be followed post-ERCP for up to 10 years. The primary outcome is development of acute pancreatitis following the index ERCP, based on standard definitions.
Acute pancreatitis is defined as new onset of pancreatic-type abdominal pain with associated elevation in serum amylase or lipase > 3 times the upper limit of normal, OR radiographic findings consistent with acute pancreatitis.
- Interval development of chronic pancreatitis [ Time Frame: 120 months ]Determine the incidence of chronic pancreatitis during prolonged follow-up. Chronic pancreatitis is defined as characteristic changes on cross sectional imaging (CT or MRI/MRCP) or ERP (Cambridge classification).
- Secondary assessment of risk factors for developing recurrent acute pancreatitis during follow-up [ Time Frame: 120 months ]A post hoc analysis will be conducted to evaluate for independent factors associated with having recurrent acute pancreatitis during follow-up

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Idiopathic recurrent acute pancreatitis, defined as two or more episodes requiring hospitalization
- ERCP with SOM planned
Exclusion Criteria:
- Chronic pancreatitis
- Pancreas divisum
- Alternate etiology identified (e.g., CBD stone, IPMN)
- Inability to perform pancreatic manometry
- Pregnancy, age < 18, incarceration
- Inability to provide informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01583517
United States, Indiana | |
Indiana University Health University Hospital | |
Indianapolis, Indiana, United States, 46202 |
Principal Investigator: | Stuart Sherman, MD | Indiana University |
Responsible Party: | Indiana University |
ClinicalTrials.gov Identifier: | NCT01583517 |
Other Study ID Numbers: |
1011003897 |
First Posted: | April 24, 2012 Key Record Dates |
Last Update Posted: | October 10, 2014 |
Last Verified: | October 2014 |
Acute pancreatitis ERCP Sphincterotomy Manometry Sphincter of Oddi dysfunction |
Pancreatitis Pancreatic Diseases Digestive System Diseases |